Overview

Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and Abraxane.
Phase:
Phase 2
Details
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborator:
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel